All News #Library
Rare Diseases
Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio
29 Jul 2023 //
HEALTH ET
FDA signs off on Reata`s Skyclarys for rare neurologic disorder
02 Mar 2023 //
FIERCE PHARMA
FDA scraps AdComm for Reata`s rare disease candidate
14 Oct 2022 //
FIERCEBIOTECH

Market Place
Sourcing Support